


# IFAPP WEBINAR


## CAR T-Cell Therapy and Ethical Aspects (patients' involvement)




Wednesday, May 29, 2024  
11:00 AM - 01:00 PM CEST

### Time Schedule

05:00 - 07:00 AM EST  
09:00 - 11:00 AM GMT  
11:00 - 01:00 PM CEST  
06:00 - 08:00 PM JST





# IFAPP WEBINAR

## CAR T-Cell Therapy and Ethical Aspects (patients' involvement)



Speaker

**DR. ANTONIO PEREZ MARTINEZ**

(UNIVERSITY HOSPITAL LA PAZ, MADRID – SPAIN)

Panelist



**DR. YASUHIKO MIYATA**

(Director of Clinical  
Development and Medical  
Affairs, Miltenyi Biomedicine  
– Japan)

Panelist



**DR. INGRID KLINGMANN**

(EFGCP, BRUSSELS –  
BELGIUM)

**Moderator:**

ANNA JURCZYNSKA (IFAPP BOO SECRETARY AND DELEGATE MADRID – SPAIN)

# IFAPP WEBINAR

## CAR T-Cell Therapy and Ethical Aspects (patients' involvement)

CAR T-cell therapy has demonstrated high response rates, particularly in certain types of blood cancers like acute lymphoblastic leukemia (ALL) and certain types of lymphoma. It has provided durable remissions in some patients who have not responded to other treatments. CAR T-cell therapy specifically targets cancer cells by recognising specific proteins (antigens) on their surface.

Besides the side effects like cytokine release syndrome (CRS) and neurotoxicity the most discussed topic is the access to treatment for patients. This in the light of the rarity of specialised centres and the expensive costs. This high cost can pose financial challenges for patients and healthcare systems, potentially limiting access to those who could benefit from the treatment.

Therefore, patients' involvement plays an important role in the ethical considerations in the CAR T-Cell therapy.

[Register in advance for this webinar](#)

After registering, you will receive a confirmation email containing information about joining the webinar.